Liselotte Nilsson
Sales & Marketing presso CLINICAL LASERTHERMIA SYSTEMS AB
Profilo
Liselotte Nilsson is currently the Vice President-Marketing at Clinical Laserthermia Systems AB since 2021.
Prior to this, she worked as the Head-Marketing at Phase Holographic Imaging AB, Marketing Manager at ProstaLund AB, and Marketing Manager at Svar Life Science AB.
Posizioni attive di Liselotte Nilsson
Società | Posizione | Inizio |
---|---|---|
CLINICAL LASERTHERMIA SYSTEMS AB | Sales & Marketing | 01/01/2021 |
Precedenti posizioni note di Liselotte Nilsson
Società | Posizione | Fine |
---|---|---|
PROSTALUND AB | Sales & Marketing | - |
Svar Life Science AB
Svar Life Science AB Miscellaneous Commercial ServicesCommercial Services Svar Life Science AB is a Swedish company that provides GMP and non-GMP bioassay services for drug development. The private company is based in Malmö, Sweden. The company specializes in using activity biomarkers to determine if deficiencies, overactivation, or dysregulation in the complement system are causing or contributing to a person's disease or condition. The company offers method development, qualification, validation, and method improvements throughout the drug development lifecycle. Anne Thjømøe has been the CEO of the company since 2022. | Sales & Marketing | - |
PHASE HOLOGRAPHIC IMAGING PHI AB | Sales & Marketing | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
CLINICAL LASERTHERMIA SYSTEMS AB | Health Technology |
PHASE HOLOGRAPHIC IMAGING PHI AB | Health Technology |
PROSTALUND AB | Health Technology |
Aziende private | 1 |
---|---|
Svar Life Science AB
Svar Life Science AB Miscellaneous Commercial ServicesCommercial Services Svar Life Science AB is a Swedish company that provides GMP and non-GMP bioassay services for drug development. The private company is based in Malmö, Sweden. The company specializes in using activity biomarkers to determine if deficiencies, overactivation, or dysregulation in the complement system are causing or contributing to a person's disease or condition. The company offers method development, qualification, validation, and method improvements throughout the drug development lifecycle. Anne Thjømøe has been the CEO of the company since 2022. | Commercial Services |
- Borsa valori
- Insiders
- Liselotte Nilsson